Cas:141895-35-4 3-(4-methoxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid manufacturer & supplier

Chemical Name:3-(4-methoxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid

CAS.NO:141895-35-4

Synonyms:O-Methyl-N-{[(2-methyl-2-propanyl)oxy]carbonyl}tyrosine;Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-O-methyl-;N-(tert-Butoxycarbonyl)-O-methyltyrosine;Boc-D-4-Methoxyphe

Molecular Formula:C₁₅H₂₁NO₅

Molecular Weight:295.331

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:462.0±40.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.523

PSA:84.86000

Exact Mass:295.141968

LogP:2.88

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like O-Methyl-N-{[(2-methyl-2-propanyl)oxy]carbonyl}tyrosine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Boc-D-4-Methoxyphe physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(tert-Butoxycarbonyl)-O-methyltyrosine Use and application,O-Methyl-N-{[(2-methyl-2-propanyl)oxy]carbonyl}tyrosine technical grade,usp/ep/jp grade.

Related News: “We’re going to further invest in research and development to continue to build our pipeline of products, in a more sophisticated way,” he says, holding up a pocket-sized wearable device and a tiny insulin pen to his screen’s camera. “We really believe in this business for the next—we hope—70 years.” 5-tert-Butyl-2-(2-dimethylamino-ethyl)-benzo[de]isoquinoline-1,3-dione manufacturers The outlay will be used to grow Takeda’s portfolio of treatments and boost capacity to manufacture additional products for the rare disease community, Stephen Hatke, Takeda’s Thousand Oaks site head, said in a YouTube video about the expansion. The company didn’t name the specific products it plans to make there. (C5H5)(CO)2W(η(3)-Me(MeO)CCHCHCOOMe) suppliers Brian McNamara, currently head of GSK’s consumer healthcare division, will continue to serve as the franchise’s CEO after it breaks away from GSK in 2022, the British pharma said Thursday. acetic acid N’-[2-(5-nitro-furan-2-yl)-pyrimidin-4-yl]-hydrazide vendor & factory “We’re going to further invest in research and development to continue to build our pipeline of products, in a more sophisticated way,” he says, holding up a pocket-sized wearable device and a tiny insulin pen to his screen’s camera. “We really believe in this business for the next—we hope—70 years.”,“The most important thing to be considered while determining a CDMO competency is their technical knowledge along with adequate expertise to accomplish the drug development till commercial scaling.